600873 Meihua Holdings Group
- 10.22
- +0.01+0.10%
Meihua Holdings Group News
Meihua Biotech (600873.SH) will distribute the 2023 cash dividend of 0.42 yuan per share on June 6
Meihua Biotech (600873.SH) announced that the company will release the 2023 annual report on June 6, 2024...
Meihua Biotech (600873.SH): Plans to increase the holdings of directors, supervisors, senior management and other core management have been implemented
Gelonghui, May 22丨Meihua Biotech (600873.SH) announced that by the close of trading on May 22, 2024, directors, supervisors, senior management and other core management increased their holdings by a total of 82.5561 million yuan (including transaction fees) through the Shanghai Stock Exchange trading system. The amount of increase in holdings has exceeded the lower limit of the amount of the current increase plan, and the implementation of this holdings increase plan has been completed.
Express News | Huatai Securities: Amino acids replace soybean meal to help food security
Investors Aren't Buying MeiHua Holdings Group Co.,Ltd's (SHSE:600873) Earnings
When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 33x, you may consider MeiHua Holdings Group Co.,Ltd (SHSE:600873) as a highly attractive investment with its
Meihua Biotech (600873.SH): 2024 Employee Stock Ownership Plan to Purchase 0.15% of Shares
Gelonghui, May 10, 丨 Meihua Biotech (600873.SH) announced that by the end of April 2024, the company's 2024 employee stock ownership plan account had purchased a total of 4,407,800 shares of the company's shares through centralized bidding transactions in the secondary market, accounting for 0.15% of the company's current total share capital (2,852,788,750 shares). The average transaction price was 10.06 yuan/share, and the transaction amount was 44,332,733 yuan (excluding transaction fees).
Is MeiHua Holdings GroupLtd (SHSE:600873) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it might be obvious
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
MeiHua Holdings GroupLtd's (SHSE:600873) Sluggish Earnings Might Be Just The Beginning Of Its Problems
MeiHua Holdings Group Co.,Ltd's (SHSE:600873) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings. SHSE
Meihua Biotech (600873): The leading multi-category layout in the global amino acid industry continues to gain strength
Key investment points: Mainly engaged in amino acid products, leading production capacity in the world. The company's products are mainly amino acids, taking into account the development of multiple categories, forming a business centered on animal nutritional amino acids, flavoring products, human medical amino acids, colloidal polysaccharides, etc.
Meihua Biotech (600873.SH): Relevant shareholders increased their total share holdings by 489.191,000 yuan
Gelonghui, April 10 | Meihua Biotech (600873.SH) announced that as of the disclosure date of this announcement, half of the implementation period of this increase plan has passed. Some holdings increase their holdings by a total of 489.191,000 yuan (including transaction fees) through the Shanghai Stock Exchange trading system through centralized bidding. The increase amount has reached and exceeded half of the lower limit of the increase in holdings plan. The implementation of this holdings increase plan has not yet been completed, and the entities that have increased their holdings will continue to implement this holdings increase plan.
104 shares received a buying rating from brokerage firms, and Meihua Biotech's target increase of 54.74%
According to Wind data, on April 9, a total of 104 stocks received a brokerage purchase rating, of which 31 stocks announced target prices. Based on the highest target price, Meihua Biotech, Hengli Petrochemical, and Jiuzhou Pharmaceutical ranked first in terms of target increases of 54.74%, 49.27%, and 46.21%, respectively. Judging from the direction of rating adjustments, the ratings of 95 stocks remained unchanged, the rating of 1 individual stock was raised, and 8 stocks were rated for the first time. In addition, 19 individual stocks received attention from many brokerage firms. **** Mouse Electric, China Exemption, and Juneyao Airlines received the highest number of ratings, with 7, 4, and 4 brokerage firms respectively commenting
Meihua Biotech (600873): Performance is in line with market expectations, and the price difference between alcohol and lysine continues to rise
Incident: On the evening of April 8, the company released its 2024 quarterly report. In the first quarter, the company achieved operating income of 6.5 billion yuan, a year-on-year decrease of 6.7%; realized net profit of 750 million yuan, a year-on-year decrease of 6.1%; achieved no deduction
Guolian Securities released a research report on April 9 stating that Meihua Biotech (600873.SH) was given a purchase rating. The main reasons for the rating include: 1) the quantity and price of feed amino acids have risen sharply, and the performance is
Guolian Securities released a research report on April 9 stating that Meihua Biotech (600873.SH) was given a purchase rating. The main reasons for the rating include: 1) the quantity and price of feed amino acids have risen sharply, and the performance is in line with market expectations; 2) actively laying out synthetic biology to open up room for growth; 3) maintaining high dividends and high repurchase policies over a long period of time. (Mainichi Keizai Shimbun)
Meihua Holdings Group's Attributable Profit Slides 6% in Q1; Shares Slide 3%
Meihua Holdings Group's (SHA:600873) attributable profit slid 6.13% year over year to 751.7 million yuan in the first quarter, according to a Tuesday filing with the Shanghai bourse. Earning per share
Meihua Holdings Logs 6.49 Billion Yuan in Food Sales Revenue in Q1; Shares Down 3%
Chinese food additive producer Meihua Holdings Group (SHA:600873) generated 6.49 billion yuan from the sales of food products in the first quarter, according to the company's filing on the Shanghai St
Meihua Biotech (600873): Leading amino acid enterprise platform achieves development
Company introduction: Amino acid leader, focusing on high dividends and employee incentives The company has developed into one of the largest enterprises with comprehensive amino acid categories and production capacity in China. Its products include animal nutritional amino acid products, food taste optimization products, and amino acids for human medical use
Meihua Biotech (600873): Price decline is dragging down revenue and waiting for the amino acid boom to recover
Incident: The company released its quarterly report on April 9, achieving revenue of 6.487 billion yuan, -6.67%, and -10.34% month-on-month; net profit to mother of 752 million yuan, -6.13% year-on-year, and -26.33 month-on-month
Express News | Meihua Biotech: Net profit for the first quarter of 2024 fell 6.13% year on year
MeiHua Holdings GroupLtd's (SHSE:600873) Five-year Earnings Growth Trails the Strong Shareholder Returns
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses is one path to excess returns. To wit, the MeiHua Holdings GroupLtd share price
Meihua Biotech (600873): Q1 net profit declined slightly year-on-year, and the amino acid boom picked up
Net profit for 24Q1 was 750 million yuan, -6% YoY /-26% YoY. Maintaining the “Buy” rating, the company released its quarterly report for the year 24 on April 8, and achieved revenue of 6.5 billion yuan in 24Q1, -7% YoY /month-on-month-
Analysis
Price Target
No Data
